Royalty Pharma plc (ticker: RPRX) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of RPRX's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. RPRX reported $630.58M in revenue and $294.69M for the period ending 2026-03-31, with operating cash flow of $718.23M. Cash and equivalents stood at $586.39M (down 46.1% year-over-year). Total assets of $19.82B exceed total liabilities of $9.88B. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
RPRX SEC Filings
Full cached SEC EDGAR filing history for RPRX, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.